NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
49.88
-0.02 (-0.04%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close49.90
Open49.48
Bid46.00 x 1400
Ask0.00 x 4000
Day's Range49.47 - 49.96
52 Week Range41.03 - 58.37
Volume1,039,207
Avg. Volume1,619,874
Market Cap120.756B
Beta0.82
PE Ratio (TTM)20.29
EPS (TTM)2.46
Earnings DateN/A
Forward Dividend & Yield1.28 (2.63%)
Ex-Dividend Date2018-03-23
1y Target Est60.40
Trade prices are not sourced from all markets
  • CNBC3 days ago

    Novozymes and Novo Nordisk sign deal to source power from Denmark’s largest wind farm

    The wind farm's 72 turbines will have a rotor diameter of 167 meters and weigh almost 900 tons each. The facility, located in the Baltic Sea, is set to be in full operation by the end of 2021. Novozymes and Novo Nordisk have signed an agreement to source power from Vattenfall’s Kriegers Flak offshore wind park, the Swedish utility said Friday.

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberg5 days ago

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

  • Top Stocks Set to Disrupt the Diabetes Market
    Motley Fool9 days ago

    Top Stocks Set to Disrupt the Diabetes Market

    Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

  • A Look at Novo Nordisk’s Biopharmaceuticals
    Market Realist11 days ago

    A Look at Novo Nordisk’s Biopharmaceuticals

    In the first quarter, Novo Nordisk’s (NVO) Hemophilia segment generated net revenues of 2.5 billion Danish kroner compared to 2.58 billion Danish kroner in the first quarter of 2017, reflecting ~3.0% YoY (year-over-year) growth.

  • NVO’s Victoza and Ozempic Could See Steady Growth in 2018
    Market Realist11 days ago

    NVO’s Victoza and Ozempic Could See Steady Growth in 2018

    Novo Nordisk’s (NVO) Victoza generated revenues of 5.99 billion Danish kroner in the first quarter, compared to 5.75 billion Danish kroner in the first quarter of 2017, reflecting ~4.0% YoY (year-over-year) growth.

  • ACCESSWIRE11 days ago

    Free Technical Reports on Novavax and Three Additional Biotech Equities

    WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin
    Market Realist12 days ago

    The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin

    In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.

  • NVO’s Tresiba and Xultophy Could See Solid Growth in 2018
    Market Realist12 days ago

    NVO’s Tresiba and Xultophy Could See Solid Growth in 2018

    Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.

  • Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver
    Market Realist12 days ago

    Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

    In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.

  • A Look at Novo Nordisk’s Financial Position
    Market Realist12 days ago

    A Look at Novo Nordisk’s Financial Position

    Novo Nordisk (NVO) reported revenues of 26.9 billion Danish kroner in the first quarter, compared to 28.5 billion Danish kroner in the first quarter of 2017, which reflected an ~5.0% year-over-year (or YoY) decline.

  • Benzinga15 days ago

    The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

    Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...

  • GlobeNewswire20 days ago

    EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr. Ando, the former Chairman of the Board of Novo Nordisk A/S (NVO), a global pharmaceutical company, brings more than 35 years of global drug development and general management experience to EyePoint. “Dr. Ando’s extensive experience across the many facets of the global pharmaceutical industry will undoubtedly be valuable as we transition into a commercial ophthalmic company with our planned U.S. launches of DEXYCU™ and, if approved, YUTIQ™,” said David J. Mazzo, Ph.D., Chairman of the Board of Directors of EyePoint Pharmaceuticals.

  • Novo Nordisk (NVO) Announces Results in Diabetes Studies
    Zacks21 days ago

    Novo Nordisk (NVO) Announces Results in Diabetes Studies

    Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

  • 5 Biggest Blockbuster Diabetes Drugs of the Future
    Motley Fool22 days ago

    5 Biggest Blockbuster Diabetes Drugs of the Future

    The diabetes market is growing rapidly. These drugs -- and drugmakers -- should be the biggest winners.

  • Bloomberg22 days ago

    Novo Says Tresiba Shows Significantly Better Blood Sugar Control

    Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....

  • Reuters23 days ago

    Novo reveals more Ozempic data on change in body weight by baseline BMI

    Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, ...

  • TheStreet.com23 days ago

    Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

    While the Trump administration touts its efforts to lower drug prices with its "blueprint," the debate over how drugs are priced and how high those prices are in the U.S. picks up speed. Patient groups elected officials and the American Medical Association are now calling on drug companies to explain how they arrive their prices for insulin. Part of the challenge for diabetics is that there is no generic form of insulin on the U.S. market.

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks24 days ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • TheStreet.com24 days ago

    Novo Nordisk Stock Rises 4% Over 2 Sessions

    is riding the success of its experimental diabetes drug's positive test results, with the shares rising 1.65% Thursday to $46.40. The stock has been rising on a successful test that pitted Novo's oral semaglutide drug against the DDP-4 inhibitor Januvia from Merck & Co. and another Novo drug called Victoza, a once-a-week injectable pen used to regulate blood-sugar levels.

  • Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
    Zacks24 days ago

    Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

    Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

  • TheStreet.com25 days ago

    Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

    Novo Nordisk A/S is having one of its best days in more than two months, with shares popping 2.58% -- their highest percentage gain since May 2 -- shortly after the market opened Thursday. NOV added $1.

  • Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
    Zacks25 days ago

    Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

    Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

  • LLY vs. NVO: Which Stock Should Value Investors Buy Now?
    Zacks26 days ago

    LLY vs. NVO: Which Stock Should Value Investors Buy Now?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
    Motley Fool28 days ago

    Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming

    Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?

  • Reuterslast month

    Novo Nordisk shares fall after report of layoffs

    Shares in Novo Nordisk (NOVOb.CO) opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets. Denmark's Novo Nordisk said in May that the new rules would cut its 2019 sales by 1-2 percent but kept its long-term operating growth forecast of 5 percent. According to Danish daily Borsen, the firm is now considering ditching the long-term target due to "uncertain and unpredictable markets".